First and only FDA-approved injectable drug treatment for Submental fullness
New Product Alert: Our office is now offering a treatment for your double chin! Recently approved by the FDA, KYBELLA™ (deoxycholic acid) injection, contours and improves the appearance of moderate to severe submental fullness, sometimes referred to as “double chin.”
WHAT IS SUBMENTAL FULLNESS?
Submental fullness can impact a broad range of adults, including both men and women, and can be influenced by several factors such as aging, genetics and weight gain and is often resistant to diet and exercise alone. According to a survey by the American Society for Dermatologic Surgery, nearly as many consumers are bothered by submental fullness (68%) as by lines and wrinkles around the eyes (71%).
HOW DOES KYBELLA WORK?
When injected into subcutaneous fat, KYBELLA™ causes the destruction of fat cells. Once destroyed, those cells cannot store or accumulate fat.
WHAT ARE THE SIDE EFFECTS?
The most common side effects are swelling, bruising, pain, numbness, redness and formation of small areas of firmness around the treatment area. KYBELLA can cause serious side effects, including trouble swallowing and nerve injury in the jaw that can cause an uneven smile or facial muscle weakness.
Find out about how you can achieve your goals and dreams today. We are honored to offer KYBELLA cosmetic treatments at the Robert Zubowski MD Center for Plastic & Reconstructive Surgery in Paramus, NJ. All procedures are performed by Dr. Robert Zubowski.
Dr. Zubowski is widely recognized as a top NJ plastic surgeon located in Paramus, New Jersey. He is board certified by the American Board of Plastic Surgery and has over two decades of surgical experience in cosmetic surgery.
For your comfort during a a Kybella treatment we now offer Pro-Nox, a patient-controlled inhaler that delivers a combination of 50% oxygen and 50% nitrous oxide to alleviate pain and anxiousness. Simply ask for it. Read more about Pro-Nox.
If you are interested in our surgical procedures click here.